Squarepoint
ACHV icon

Squarepoint’s Achieve Life Sciences ACHV Stock Holding History

Squarepoint’s Portfolio ACHV Stock Details ACHV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-19,658
Closed -$57.8K – 4332
2026
Q1 		$57.8K Sell
19,658
-144,947
-88% -$644K ﹤0.01% 4127
2025
Q4 		$818K Sell
164,605
-208,474
-56% -$909K ﹤0.01% 2780
2025
Q3 		$1.18M Buy
373,079
+359,642
+2,677% +$987K ﹤0.01% 2550
2025
Q2 		$30.4K Buy
+13,437
New +$38.3K ﹤0.01% 4361
2025
Q1 		– Sell
-17,519
Closed -$61.7K – 4481
2024
Q4 		$61.7K Buy
+17,519
New +$79.4K ﹤0.01% 4807
2024
Q1 		– Sell
-23,105
Closed -$95.2K – 3944
2023
Q4 		$95.2K Buy
23,105
+10,631
+85% +$46.3K ﹤0.01% 3761
2023
Q3 		$53.6K Sell
12,474
-9,498
-43% -$47.9K ﹤0.01% 3630
2023
Q2 		$114K Buy
+21,972
New +$154K ﹤0.01% 3340
2020
Q4 		– Sell
-10,093
Closed -$84K – 2858
2020
Q3 		$84K Buy
+10,093
New +$92.6K ﹤0.01% 2315

Other funds holding ACHV

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Squarepoint's ACHV Position: Q2 2026 in Review

Squarepoint sold out of Achieve Life Sciences (ACHV) in Q2 2026, closing a stake of 19,658 shares — an estimated $57.8K sold.

Squarepoint first reported a position in ACHV in Q3 2020 and held it in 9 quarters. The position peaked at $1.18M in Q3 2025. 111 funds tracked by Wall St. Rank hold ACHV as of Q2 2026.

  • Squarepoint reported no remaining Achieve Life Sciences position as of Q2 2026 after selling out during the quarter.
  • Squarepoint sold 19,658 Achieve Life Sciences shares in Q2 2026, an estimated $57.8K.
  • Squarepoint first reported a position in Achieve Life Sciences in Q3 2020 and held it in 9 quarters.
  • Squarepoint's Achieve Life Sciences position peaked at $1.18M in Q3 2025.
  • 111 funds tracked by Wall St. Rank held Achieve Life Sciences as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.